Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

A legfontosabb adatok

Ki végzi
Merck Sharp & Dohme LLC
Hol
Las Vegas (Egyesült Államok)A helyszín megnézéseMég 1 másik országban, 1 helyszínen
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2025. márc. 26.
Várható befejezés
2031. márc. 18.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Pembrolizumab
  • Paclitaxel
  • Carboplatin
  • Doxorubicin (hydrochloride)
  • Boserolimab
  • Epirubicin Hydrochloride
  • Cyclophosphamide
  • Capecitabine
  • Olaparib (if approved/available locally)
A regiszteradat frissítve
2026. február 19.
Miért állt le
Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • The main inclusion criteria include but are not limited to the following:
  • Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as tumor stage T1c, nodal stage N1-2, or tumor stage T2-4, nodal stage N0-2
  • Has provided a core needle biopsy for tissue diagnosis of the current breast cancer less than 29 days prior to the date of informed consent
  • Has centrally confirmed diagnosis of BC that is triple-negative based on the American Society of Clinical Oncology/College of American Pathologists guidelines
  • Has Eastern Cooperative Oncology Group performance status of 0 or 1 performed within 28 days before treatment randomization
  • Has left ventricle ejection fraction of ≥50% as assessed by echocardiogram or multigated acquisition scan performed at screening
  • Has a history of exposure to anthracycline; participants can be eligible after completion of a Sponsor consultation form, if cumulative lifetime doses are as follows: Doxorubicin <100 mg/m2, Epirubicin <180 mg/m2, Mitoxantrone <40 mg/m2, Idarubicin <22.5 mg/m2. Note: If another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of 100 mg/m2 of doxorubicin

Ki nem vehet részt

  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior systemic anticancer therapy
  • Has undergone excisional biopsy of the primary tumor and/or axillary lymph node dissection prior to study treatment
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has severe hypersensitivity (Grade ≥3) to pembrolizumab, any investigational agent or study intervention, any of its excipients, and/or to another biologic therapy
  • Has uncontrolled or significant cardiovascular disease
  • Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has active autoimmune disease that has required systemic treatment in the past 2 years with need for disease modifying agents such as corticosteroids or immunosuppressive drugs
  • Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has a history of allogeneic tissue/solid organ transplant
  • Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein-4 [CTLA-4], OX-40 [cluster of differentiation (CD) 134], or CD137)
  • The main exclusion criteria include but are not limited to the following:
  • Has documented Grade ≥2 peripheral neuropathy

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 1 helyszínen

  • Optum Care Cancer Center (Site 0004)Las Vegas, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC). The goals of this study are to learn about the safety of boserolimab given with standard treatment before surgery and to learn if people tolerate it and how many people have no signs of cancer in the tissues and lymph nodes removed during surgery.

A vizsgálat 2 csoportja

  • Pembrolizumab+ Paclitaxel+ CarboplatinMár használt kezelés, összehasonlításként

    Participants will receive pembrolizumab PLUS paclitaxel PLUS carboplatin followed by pembrolizumab PLUS doxorubicin hydrochloride or epirubicin hydrochloride and cyclophosphamide as neoadjuvant therapy prior to surgery. In adjuvant therapy participants will receive pembrolizumab PLUS optional additional adjuvant treatment of physician's choice (TPC), capecitabine or olaparib.

    Kezelés: Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin (hydrochloride), Epirubicin Hydrochloride, Cyclophosphamide, Capecitabine és Olaparib (if approved/available locally)

  • Pembrolizumab+Boserolimab+Paclitaxel+ CarboplatinA vizsgált kezelés

    Participants will receive pembrolizumab PLUS boserolimab PLUS paclitaxel PLUS carboplatin followed by pembrolizumab PLUS doxorubicin hydrochloride or epirubicin hydrochloride and cyclophosphamide PLUS boserolimab as neoadjuvant therapy prior to surgery. In adjuvant therapy participants will receive pembrolizumab PLUS optional additional adjuvant treatment of physician's choice (TPC), capecitabine or olaparib.

    Kezelés: Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin (hydrochloride), Boserolimab, Epirubicin Hydrochloride, Cyclophosphamide, Capecitabine és Olaparib (if approved/available locally)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer
A regiszteradat frissítve
2026. február 19.